Study finds bariatric surgery significantly reduces risk of chronic kidney disease progression compared to GLP-1 drugs in patients with obesity and diabetes
MHRA concludes there is no evidence to support a connection between GLP-1 receptor agonists, including Novo Nordisk's Wegovy, and suicide-related risks
Many gained access to GLP-1s through Medicaid’s decision in late 2024 to cover these weight loss drugs. But these medications remain out of reach for millions of patients across the US.